| S type lectin | <protein> One of two classes of lectin produced by animal cells. The classification of animal lectins into two classes, the other being the C type, was originally proposed by K.Drickamer. The carbohydrate binding activity of the S type lectins requires their cysteines to have free thiols and does not need divalent cations (c.f. C type lectins). They mostly have molecular masses in the range 14-16 kD and often form dimers and higher oligomers. The carbohydrate recognition domain contains a number of critically conserved amino acids and largely binds to _ galactosides. S type lectins certainly occur as cytoplasmic proteins but the existence of extracellular S type lectins is still a matter of debate. (18 Nov 1997) |
|---|---|
| nomenclatural type | The constituent element of a taxon to which the name of the taxon is permanently attached; the type of a species is preferably a strain (in special cases it may be a description, a preserved specimen or preparation, or an illustration); the type of a genus is a species; and the type of an order, family, or tribe is the genus on whose name the name of the higher taxon is based. (05 Mar 2000) |
| nutritional type cerebellar atrophy | A restricted type of cerebellar cortical degeneration, affecting particularly the Purkinje cells of the anterior and superior vermis; probably caused by thiamin deficiency; most frequently seen in chronic alcoholics and then called alcoholic cerebellar degeneration. (05 Mar 2000) |
| delayed type hypersensitivity | <immunology> Hypersensitivity (increased reaction by the body to a foreign substance such as an antigen or allergen) that does not appear until 24 to 48 hours after the body is exposed to the foreign substance. (09 Oct 1997) |
| Swiss type agammaglobulinaemia | Group of rare congenital disorders characterised by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an x-linked or autosomal recessive defect. About half of the patients with autosomal recessive scid are deficient in the enzyme adenosine deaminase. (12 Dec 1998) |
| deoxyribonucleases, type III site-specific | <enzyme> Enzyme systems composed of two subunits and requiring ATP and magnesium for endonucleolytic activity; they do not function as atpases. They exist as complexes with modification methylases of similar specificity. The systems recognise specific short DNA sequences and cleave a short distance, about 24 to 27 bases, away from the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers. Registry number: EC 3.1.21.5 (12 Dec 1998) |
| deoxyribonucleases, type II site-specific | <enzyme> Enzyme systems containing a single subunit and requiring only magnesium for endonucleolytic activity. The corresponding modification methylases are separate enzymes. The systems recognise specific short DNA sequences and cleave either within, or at a short specific distance from, the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers. Registry number: EC 3.1.21.4 (12 Dec 1998) |
| deoxyribonucleases, type I site-specific | <enzyme> Enzyme systems containing three different subunits and requiring ATP, s-adenosylmethionine, and magnesium for endonucleolytic activity to give random double-stranded fragments with terminal 5'-phosphates. They function also as DNA-dependent atpases and modification methylases, catalyzing the reactions of EC 2.1.1.72 and EC 2.1.1.73 with similar site-specificity. The systems recognise specific short DNA sequences and cleave at sites remote from the recognition sequence. Enzymes from different microorganisms with the same specificity are called isoschizomers. Registry number: EC 3.1.21.3 (12 Dec 1998) |
| diabetes, type 1 | Insulin dependent diabetes or juvenile diabetes. (12 Dec 1998) |
| diabetes, type 2 | Non-insulin dependent diabetes, adult-onset diabetes or insulin-resistant diabetes. (12 Dec 1998) |
| disease, gaucher's type 1 | A progressive genetic disease caused by a defect in an enzyme. The enzyme, called glucocerebrosidase, is needed to break down the chemical glucocerebroside. The enzyme defect in persons with Gaucher's disease (GD) leads to the accumulation of glucocerebroside in the spleen, liver, and lymph nodes. The most common early sign is enlargement of the spleen (located in the upper left abdomen). Other signs include low red blood cell counts (anaemia), a decrease in blood clotting cells (platelets), increased pigmentation of the skin, and a yellow fatty spot on the white of the eye (a pinguecula). Severe bone involvement can lead to pain and collapse of the bone of the hips, shoulders, and spine. The GD gene is on chromosome 1. The disease is a recessive trait. Both parents carry a GD gene and transmit it for their child with the disease. The parents' risk of a child with the disease is 1 in 4 with each pregnancy. This type of Gaucher's disease (noncerebral juvenile Gaucher's disease) is most common in Ashkenazi Jews (of European origin) and is the most common genetic disease among Jews in the United States. (12 Dec 1998) |
| immunization, haemophilus influenzae type b | See immunization, hib. (12 Dec 1998) |
| influenza type a | A common acute viral infection of the nasopharynx and respiratory tract which occurs in epidemic forms. A common cause is the Influenza a virus. Annual vaccination is recommended for those in high risk groups (health care workers, elderly and immunocompromised) for influenza infection. Common symptoms include runny nose, fever, weakness, headache, body aches, muscle aches, nausea and back pain. Treatment of symptoms has been successful with amantadine or rimantadine. (27 Sep 1997) |
| interferon type I | <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta). Pharmacological action: antineoplastic agent, antiviral agents. (12 Dec 1998) |
| interferon type II | <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease. Pharmacological action: antineoplastic agent, antiviral agents. Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced) (12 Dec 1998) |